GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BUE:AMGN) » Definitions » PB Ratio

Amgen (BUE:AMGN) PB Ratio

: 0.46 (As of Today)
View and export this data going back to . Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-23), Amgen's share price is ARS9610.00. Amgen's Book Value per Share for the quarter that ended in Dec. 2023 was ARS21,010.01. Hence, Amgen's PB Ratio of today is 0.46.

The historical rank and industry rank for Amgen's PB Ratio or its related term are showing as below:

BUE:AMGN' s PB Ratio Range Over the Past 10 Years
Min: 3.28   Med: 8.62   Max: 148.84
Current: 23.19

During the past 13 years, Amgen's highest PB Ratio was 148.84. The lowest was 3.28. And the median was 8.62.

BUE:AMGN's PB Ratio is ranked worse than
98.03% of 963 companies
in the Drug Manufacturers industry
Industry Median: 1.91 vs BUE:AMGN: 23.19

During the past 12 months, Amgen's average Book Value Per Share Growth Rate was 69.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -10.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -14.70% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -14.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Amgen was 69.30% per year. The lowest was -26.10% per year. And the median was 16.00% per year.

Back to Basics: PB Ratio


Amgen PB Ratio Historical Data

The historical data trend for Amgen's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.49 0.75 1.55 1.33

Amgen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.55 0.99 0.75 0.88 1.33

Competitive Comparison

For the Drug Manufacturers - General subindustry, Amgen's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen PB Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Amgen's PB Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's PB Ratio falls into.



Amgen PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Amgen's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=9610.00/21010.011
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Amgen  (BUE:AMGN) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Amgen PB Ratio Related Terms

Thank you for viewing the detailed overview of Amgen's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen (BUE:AMGN) Business Description

Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (BUE:AMGN) Headlines

From GuruFocus

Amgen Inc at Evercore ISI HealthCONx Conference Transcript

By GuruFocus Research 01-22-2024

Amgen Inc at Wells Fargo Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Amgen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Amgen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Amgen Inc Investor Call Transcript

By GuruFocus Research 01-22-2024

Amgen Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-22-2024